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1. Abstract
The clinical impact of neural prostheses has been inhibited by a lack of functional stability of the devices
due to acute and chronic reactive tissues' responses in the brain. However, prosthetic stability could be improved
via local drug administration or delivery of siRNA to mitigate the reactive tissues using microfluidic probes.
Neural prosthetic probes have been previously developed, but had asymmetric and uneven distribution of fluid
delivery to brain phantoms.

Therefore, probes with different geometries and fluid delivery pores (holes ranging

from 10 to 20 µm) were tested for functionality in vitro using a crystal violet/PBS solution. Compound light
microscopy and image capture were utilized to record the diffusion of solution from probes into 1% w/v agarose.
Solution diffusion was observed for 30 minutes and diffusion radii were observed for all probe geometries and
hole diameters, thus confirming probe functionality. With functionality established, solution release from probes
was characterized in vitro using Texas-Red labeled dextran pumped into agarose brain phantoms (1% w/v) at a
constant rate. Fluorescence microscopy with automated image capture was employed to record the release profile
of Texas-Red dextran. Release was monitored for 10 minutes and analyzed using Nikon Elements image analysis
software. A significant difference in fluid delivery was observed for different probe geometries and hole diameters.
The results suggest these novel probe designs could provide a more symmetric and even distribution of local drug
or siRNA delivery during intervention treatment of reactive tissue in response to neural prostheses implantation.
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2. Introduction
Technologies aimed at extracting information directly from the brain are a key component in prosthetic
systems intended to restore sensory or motor function to patients suffering from the breakdown of normal signaling
pathways. Establishing a stable Brain-Computer Interface (BCI) provides an alternative signal pathway that allows
activity from the brain to be recorded, processed, analyzed, and used to control complex prosthetic and
communication systems.1However, the insertion of neural prosthetic devices has been found to elicit reactive
responses from both vasculature and nervous tissue. Ultimately these responses prevent the successful integration
of prosthetic devices into the CNS. Numerous studies have shown that nervous tissue reacts to implanted neural
prosthetic devices through a series of events, consisting of immediate-, early-phase, and chronic-responses.2 The
immediate-response (<1 hr) to devices begins within minutes following implantation. By 30 min post-insertion,
neuronal soma near the insertion site undergo morphological changes indicative of neural degeneration. 3,4 The
early-phase response (1–7 days) is primarily inflammation, and includes damage to neuro-vasculature, activation
of mitogen-activated protein kinase signaling cascades in neurons and glia, and activation of resident microglia
and infiltrating leukocytes. Reduced cerebral blood flow following device insertion can also initiate a cascade of
events leading to ischemia. The resulting hypoxia and hypercapnia can eventually lead to impairment of cellular
ionic homeostasis.5 Initially, astrocytes maintain homeostasis by scavenging potassium and glutamate, however,
these cells ultimately assume classic reactive profiles, including hypertrophy and expression of glial fibrillary
acidic protein (GFAP) and vimentin.6 Reactive astrocytes exhibit maximal GFAP immunoreactivity between 3-7
days post-insertion, with reactive cells found to extend as far as several hundred microns from the initial insertion
site.7,8 Activated microglia and foreign body giant cells also contribute to the insulation of implanted devices. The
chronic response (>6 weeks) is characterized by a hyper-trophic reaction from reactive astrocytes. This results in
the formation of a glial-fibroblastic sheath that functions as a diffusive barrier, insulating the device, and reducing
the ability of the device to communicate with surrounding nervous tissue. 4,9 Numerous studies have demonstrated
the decrease in the long-term performance of neural prosthetic devices following implantation. In a study by
Rousche and Normann of 11 implanted electrodes, only four remained active after 5 months.10 Similarly, Williams
et al. found that of eight implanted electrode arrays, three failed within the first 15 weeks of implantation. 11 More
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recently, Nichols et al. have reported a 40% drop in electrode viability over 18 months of implanted devices.12 In
order to develop BCI technology, two intervention strategies have been devised.
Pharmacological intervention via systemic injections or slow release inflammatory agents from polymers
has been shown to alter the tissue responses around implanted devices.13,14 Although systemic injection is an
effective and easy intervention, it is not viable over time because of the side effects associated with long-term use
of inflammatory drugs. Local drug delivery however will not present such side effects and will reduce the amount
of required drug, eliminate the possibility of peripheral metabolism, circumvent the blood-brain barrier, and
provide immediate access to target tissue. Channels built into microfluidic probes can provide a means of local
drug delivery, subsequently suppressing reactive tissues’ responses and stimulating device functional stability.
The other intervention strategy is the utilization of signal interfering RNA, siRNA. RNA interference,
RNAi, is mediated by the assembly of a nuclease complex that leads to homologous mRNA degradation. When
cells detect dsRNA, Dicer, an RNase III-like enzyme, processes the long duplexes into 20-25 bp siRNAs in what
is called the RNAi initiating step. In the effector step of RNAi, the siRNA enters an RNAi specific nuclease
complex known as the RNA-Induced Silencing Complex (RISC). The siRNA is unwound, exposing the antisense
strand. This strand binds to the complementary mRNA, and the mRNA is cut by RISC in the center region of the
guiding siRNA strand, destroying the mRNA and preventing the creation of protein.; knocking down expression
of specific genes.15 Essentially any gene with a known sequence can be targeted based on sequence
complementarity with an appropriate siRNA. This makes siRNAs a useful tool for gene function and drug target
validation.

Figure 1. Left panel. siRNA structure. siRNA’s are 20-25 bp long dsRNA molecules that have a characteristic two nucleotide
3′ overhang. Right panel. Mechanism of siRNA interference. RNAi is a novel strategy for the development of antisense
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therapeutics that can result in the potent, long-lasting, post-transcriptional silencing of specific genes. RNAi mechanisms
can involve either the degradation of target RNA (short interfering RNA, siRNA), or cause translational arrest of the target
RNA (micro RNA, miRNA).16

Our experiments with neural probe devices will be performed in vitro and as such will not require the use
of siRNA. However, another molecule must be used that is safe for use in vivo (for data correlation). Dextran is a
complex, branched glucan (polysaccharide made of many glucose molecules) composed of chains of varying
lengths (from 10 to 150 kilodaltons). The straight chain consists of α-1,6 glycosidic linkages between glucose
molecules, while branches begin from α-1,4 linkages (and in some cases, α-1,2 and α-1,3 linkages as well). Dextran
is synthesized from sucrose by certain lactic-acid bacteria, the best-known being Leuconostoc mesenteroides and
Streptococcus mutans.17
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3. Methods and Materials
3.1 Fluidic probe design and fabrication
Microfluidic neural prosthetic devices were fabricated using photolithographic patterning of SU-8
photoresist (Microchem Inc., Newton, MA) using previously-reported techniques.18 The process flow for
fabricating channels in SU-8 polymer has been previously reported by Gracias, et al.18 Briefly, silicon wafers were
spin coated with an approximately 50 m layer of SU-8 photoresist and then photolithographically patterned to
establish the base of the devices.

A second layer of SU-8, approximately 75 m thick, was then spun onto the

wafer and subsequent lithographic steps were performed to define the sidewalls and topmost (~5m) covering.
The wafer was then developed in SU8 developer overnight to define and release the devices. These process steps
are illustrated in Figure 2.

Figure 2. Fabrication strategy for probe devices. A layer of SU-8 photoresist is spin-coated onto a silicon wafer (a)
followed by photolithographic pattering of the base of the device (b). A second layer of photoresist is spin-coated onto the
wafer and sidewalls (c) and a top layer (d) are defined via photolithographic patterning.

Several different probe geometries were fabricated and tested. Examples of probe geometries are illustrated in
Figure 3.
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a.

c.

b.

d.

Figure 3. Geometries of fabricated probes. (a) and (b) show a probe with “full-length” geometry, while (c) and (d) show a
probe with “tip only” geometry. Images (b) and (d) were captured using a Nikon compound light microscope and Micron
software.

3.2 Acute insertion/diffusion system
Fabricated microfluidic probes were inserted into approxiamtely 6 inch long segments of polyimide tubing
(Small Parts), with an inner diameter of either 0.020 cm or 0.025 cm, using a stereoscope. Polyimide was used
because it is light, flexible, and resistant to heat and chemicals. Gaps between the probe and polyimide tubing were
sealed using Super Silicone Sealant (3M, Saint Paul, MN). Once assembled, devices were allowed to dry overnight
before use.
To create a staining solution, crystal violet (CV) dye was dissolved in phosphate buffer saline (PBS) to
produce a 2% crystal violet solution (CVS). CV is a bactericide and the primary agent used in the Gram Stain Test.
It was used in this experiment because of its readily identifiable color. PBS was used in this experiment to maintain
a constant pH and the osmolarity and ion concentrations of the solution match those of the human body. Once
CVS was generated, it was pumped through 0.1" ID Tygon microbore tubing via a syringe pump (New Era Pump
System Inc., Wantagh, NY) to prime the neural probes. Once the probe was primed (fluid observed to be diffusing
from probe) the probe was inserted into the 1 % w/v agarose and the syringe pump was shut off. Then, the CVS
was allowed to diffuse for 30 minutes into agarose gel. 1% w/v agarose gel was used in this experiment because
it most closely resembles the consistency and fluidity of the human brain in vivo. An image was captured every
60 seconds at 4x magnification using a compound-light microscope and Micron software (Micron Technology
Inc., Boise, ID). Time was recorded using a digital multi-track laboratory stopwatch.
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Once functionality of the probes was established, different geometries and hole diameters (from 10 µm
to 20 µm) were characterized using fluorescence microscopy. The probes were assembled as previously described,
but with smaller segments of polyimide tubing, approximately 3 inches. A 50 µL Hamilton Co. (Reno, NV) 705N
microsyringe loaded with Texas-Red Dextran (TRD) placed in a micron pump was attached to the probes via tygon
tubing. TRD was used because its molecular weight mimics that of siRNAs; approximately 3 kDa and Texas-Red
is a red fluorescent dye that can be excited by λ= 595-605 nm. With the microsyringe attached to the probe, TRD
was pumped to the probes to prime them. Once primed, probes were inserted into agarose brain phantoms (1%
w/v) and TRD was pumped at a rate 0.05 µL/minute for 10 minutes. Images were captured every 10 seconds for
10 minutes via automated programming supplied by NIS-Elements Basic Research Elements software and a Nikon
Eclipse 80i compound light microscope (Nikon Instruments Inc, Melville, NY). During image capture, probes
were exposed to fluorescent light, λ= 595-605 nanometers, for 100 milliseconds with the ND-4 light filter of the
microscope on. Data was extracted from the images and imported to Microsoft Excel using the same software.
Once imported the data were analyzed and plotted using Microsoft Excel.
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4. Results and Discussion
4.1 Initial characterization of fluid delivery from probes
After fabrication of probe devices, with associated microtubing, we sought to evaluate their performance
for delivery of fluids into brain phantoms (1% w/v agarose). As described in the methods section, crystal violet
solution (CVS) was pumped into brain phantoms while observing the process under bright field microscopy.
Images collected during these tests are shown below (Figures 4-5).

Figure 4 shows probes with tip-only

geometries, while Figure 5 shows probes with full-length geometries. Hole diameter was varied for both fulllength and tip-only geometries (reflected in the columns of Figures 4-5). In these figures, CVS can be seen
diffusing out of the micropores in these devices, into to the brain phantoms.

Diffusion of CVS confirmed probe

functionality (i.e., fluid could be released from the micropores and would diffuse into the brain phantom). Images
of CVS diffusion were recorded for both geometries tested and of the hole diameters used (10 µm, 15 µm, and 20
µm). Diffusion varied by probe geometry slightly, while diffusion radii varied greatly according to hole diameter
(Figures 4-5).

15 um
holes

20 um
holes

30
min

0
min

10 um
holes

Figure 4. Release of CVS from probes with tip only geometries in agarose brain phantoms (1% w/v). Images from the top
row display probes at time of insertion, time = 0 minutes. Images from the bottom row display probes at end of diffusion,
time = 30 minutes. Each column represents a probe with a varying diameter of micropores (10 µm, 15 µm, and 20 µm
respectively). Images were captured using bright-field microscopy and Micron software. Scale = 100 µm.

10 um
holes

15 um
holes

20 um
holes

30
min

0 min
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Figure 5. Release of CVS from probes with full-length geometeries in agarose brain phantoms (1% w/v). Images from the
top row display probes at time of insertion, time = 0 minutes. Images from the bottom row display probes at end of diffusion,
time = 30 minutes. Each column represents a probe with a varying diameter of micropores.(10 µm, 15 µm, and 20 µm
respectively). Images were captured using bright-field microscopy and Micron software. Scale = 100 µm.

The results show that the shape of a probe's diffusion radius is more heavily influenced by probe geometry,
while the size of a probe's diffusion radius is more heavily influenced by the size of the probe's micropores.
Specifically, probes with a tip only geometry tend to have a diffusion radius concentrated on the tip and the middle
of the probe, while probes with a full-length geometry tend to have a consistent diffusion radius from the tip to the
shank of the probe. It should be noted that in probes with a full-length geometry and either 15 µm or 20 µm pores
do not always have a uniform diffusion from tip to shank, because the pores are larger, the diffusion radius does
not always reach the probe's tip. This problem was more frequently observed with probes with 20 µm pores versus
probes with 15 µm pores. Probes with larger micropores (20 µm) tend to have a larger diffusion radius, while
probes with smaller micropores (10 µm) tend to have a smaller diffusion radius. Given this information, it is logical
to deduce that a probe with a full-length geometry and either 10 or 15 µm pores will give the most consistent
diffusion radius, while probes with a tip only geometry will give a more localized diffusion radius. Additionally,
probes with larger micropores will be able to deliver their contents more quickly than probes with smaller
micropores. This information may prove useful when considering the target area of drug/siRNA delivery; it is
logical to deduce that probes with 20 µm pores would be suited for interventions involving immediate reactive
tissue responses, while probes with 15 µm pores would be suited for interventions involving early phase reactive
tissue responses, and probes with 10 µm pores would be suited for interventions involving chronic reactive tissue
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responses. In an immediate reactive tissue response, tissue reacts to a neural prosthetic probe upon implantation,
with minutes. In order to effectively counteract that action, one would want a device that allows for the most rapid
delivery of fluid (i.e. a probe with 20 µm pores). In an early reactive tissue response, tissue reacts to a neural
prosthetic probe within days of implantation, generally 1-7. To counteract this type of response, one would want
a device that allows for moderate delivery of fluid (i.e. a probe with 15 µm pores). In a chronic reactive tissue
response, tissue reacts to the presence of a neural prosthetic probe within weeks. To counteract this type of
response, one would want a device that allows for gradual delivery of fluid (i.e. a probe with 10 µm pores).

4.2 Quantitative characterization of fluid delivery from probes using fluorescently
labeled dextran
Initial experiments with CVS diffusion from neural prosthetic probes gave qualitative information about
fluid delivery to brain phantoms.

To provide a quantitative comparison among different probe geometries and

hole diameters, the aforementioned experimental procedures were modified. Delivery of a fluorescently labeled
high molecular weight compound (Texas-Red dextran, 3 kDa), in lieu of CVS, provides a substantial mimic of the
prospective drugs and/or siRNA intended for CNS delivery by these devices.

Fluorescent labeling of dextran

allowed for quantitative fluorescence microscopy and post-imaging analysis (densitometry/intensity–based
analysis). For this study, all of the same probe geometries and hole diameters were used (as compared to the
CVS study).

As described in the methods section, Texas-Red labeled dextran (TRD) was pumped into brain

phantoms and successive fluorescence images were collected over a 10 minute period (at a rate of one image every
10 seconds) using automated image capture software; it has been previously determined that 10 minutes is the
maximum infusion time for in vivo work. Sample images from these experiments are shown below (Figures 6-7).
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15 um holes
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5 min

0 min

10 um holes

Figure 6. Release of TRD from probes with tip only geometries in agarose brain phantoms (1% w/v). TRD was pumped at a
rate of 0.05 µL/minute for 10 minutes. To capture an image, probes were exposed to fluorescent light for 100 milliseconds at
λ = 595-605 nanometers. Images from the top row display probes at the time of insertion, time = 0 minutes. Images from the
bottom row display probes at the midway point, time = 5 minutes. Orange dotted lines represent the location of the probes in
the images. The tip of the probe is on the left side of each image, while the shank (connected with the polyimide tubing) is on
the right side. Each column represents a probe with a varying diameter of micropores.(10 µm, 15 µm, and 20 µm respectively).
Images were captured using Nikon Elements Basic Research software.
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Figure 7. Release of TRD from probes with full-length geometries in agarose brain phantoms (1% w/V). TRD was pumped
at a rate of 0.05 µL/minute for 10 minutes. To capture an image, probes were exposed to fluorescent light for 100 milliseconds
at λ = 595-605 nanometers. Images from the top row display probes at the time of insertion, time = 0 minutes. Images from
the bottom row display probes at the midway point, time = 5 minutes. Orange dotted lines represent the location of the probes
in the images. The tip of the probe is on the left side of each image, while the shank (connected with the polyimide tubing) is
on the right side. Each column represents a probe with a varying diameter of micropores (10 µm, 15 µm, and 20 µm
respectively). Images were captured using Nikon Elements Basic Research software.

These results confirm the findings of the qualitative CVS test; both probe geometries, as well as the three
different sizes of micropores are functional in the delivery of solution to agarose brain phantoms. The results show
that the shape of a probe's diffusion radius is more heavily influenced by probe geometry, while the size of a
probe's diffusion radius is more heavily influenced by the size of the probe's micropores. Specifically, probes with
a tip only geometry tend to have a diffusion radius concentrated on the tip and the middle of the probe, while
probes with a full-length geometry tend to have a consistent diffusion radius from the tip to the shank of the probe.
It should be noted that in probes with a full-length geometry and either 15 µm or 20 µm pores do not always have
a uniform diffusion from tip to shank, because the pores are larger, the diffusion radius does not always reach the
probe's tip. The problem was more frequent with probes with 20 µm pores versus probes with 15 µm pores.
Probes with larger micropores (20 µm) tend to have a larger diffusion radius, while probes with smaller micropores
(10 µm) tend to have a smaller diffusion radius. Given this information, it is logical to deduce that a probe with a
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full-length geometry and either 10 µm pores will give the most consistent diffusion radius, while probes with a
tip only geometry will give a more localized diffusion radius. Additionally, probes with larger micropores will be
able to deliver their contents more quickly than probes with smaller micropores. This information may prove useful
when considering the target area of drug/siRNA delivery; it is logical to deduce that probes with 20 µm pores
would be suited for interventions involving immediate reactive tissue responses, probes with 15 µm pores would
be suited for interventions involving early phase reactive tissue responses, and probes with 10 µm pores would be
suited for interventions involving chronic reactive tissue responses.
In addition to substantiating the CVS results, the TRD results assert that our probe designs can deliver

fluid at least 500 µm into agarose brain phantoms (1% w/v). This information is useful because reactive
tissue responses typically radiate 500 µm around a neural prosthetic probe. Therefore it is possible for
our probe design to deliver fluid to the necessary parameters. As a result, little if any modification needs
to be made to our current probe designs.
The TRD results also provide an opportunity to characterize probes quantitatively. Using Nikon Elements
software, we were able to calculate densitometry at three different locations along the probe (the shank, middle,
and tip respectively) from the probe face to 500 µm away from the probe face, 500 data points per location per
timepoint. With this ability, we were able to observe the densitometry vary at each location as time progressed.
Given the vast number of images, (61 for every probe tested) we were not able to quantitatively analyze every
timepoint. We selected 3 timepoints at one distance from the probe, 500 µm, that we thought would demonstrate
the observable variance in densitometry most clearly (time = 0 minutes, 5 minutes, and 10 minutes). We extracted
this data from each of the probe's recorded time-lapse images and analyzed it using Microsoft Excel. The results

of this analysis are shown below (Figures 8-9).
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Figure 8. Comparison of fluorescence variance amongst probes with full-length geometries and either 10 µm, 15 µm, or 20
µm pores (see key). The graphed data represents the fluorescence intensity measured at 500 µm away from the probe face
along its tip, middle, and shank. Fluorescence intensity was measured and extracted using Nikon Elements software. Error
bars represent the standard deviation between at least 3 independent probe experiments for each condition.
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Figure 9. Comparison of fluorescence variance amongst probes with full-length geometries and either 10 µm, 15 µm, or 20
µm pores (see key). The graphed data represents the fluorescence intensity measured at 500 µm away from the probe face
along its tip, middle, and shank. Fluorescence intensity was measured and extracted using Nikon Elements software. The tip
of the probe is on the left side of each image, while the shank (connected with the polyimide tubing) is on the right side.
Note: at 10 minutes along the probe shank 2 out 3 micropore sizes reach the limit of intensity, 4095 nm, thereby nullfiying
the standard deviation.

These figures quantitatively demonstrate the qualitative observations from the CVS and TRD
releases. Fluorescence intensity for probes with tip only geometries is highest at the tip, as expected. The
charts also demonstrate our earlier qualitative observations. Larger micropores are associated with the
release of more fluid. However, the overall trend of release in probes with tip only geometries is
maintained regardless of micropore diameter; decreasing fluid release from the tip of the probe to the
shank. Fluorescence intensity for probes is more consistent along the entirety of the probe. There is
another substantial difference in geometries that the charts show; as time progresses pore size does not
heavily influence fluorescence intensity for probes with full-length geometries. In the bottom graph in
Figure 9, the fluorescence intensities for different pore diameters are relatively similar. This information
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is critical when considering how to mediate immediate reactive tissue responses and should be given
due consideration.
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5. Conclusions
From previous work, it has been observed that reactive tissue responses radiate at least 500 µm from
inserted neural probe device. The in vitro results from this study suggest that fluid delivery is possible past 500
µm with our probe design.
We observed that fluid delivery was most uniform from probes with a full-length geometry and 10 µm
pores. Tip only geometries provided a more localized delivery relegated to the probe's tip and shank, while larger
pore diameters yielded skewed delivery of fluid asymmetrically along the length of the probe. Specifically, fulllength probes with larger pores, 20 µm, resulted in fluid delivery towards the shank (end connected to polyimide
tubing) of the probes.
One caveat to these observations is that after 10 min of fluid delivery, Texas-Red dextran had diffused at
least 500 um away from the probe along the entire length, regardless of geometry or hole diameter.

These results

indicate that all of the probes tested could be effective for delivery of drugs and/or siRNA to tissues during
implantation.

However, uniform distribution of fluid would be ideal to control overall dose of drug/siRNA

delivered.
From these results, it may be possible for our current probe design to be utilized successfully in combating
reactive tissue responses in their entirety. Furthermore, intervention can be mediated based on the probe geometry
and/or pore diameter used. Consequently, a potential approach for handling reactive tissues’ responses has been
presented. Although this experiment represents the elementary stages of developing a viable clinical intervention
strategy, the improvement of bio-compatibility and long-term stability of implantable neural prostheses seems
possible.

The next logical step in this process is to attempt to correlate the in vitro results to in vivo results.
If tat is accomplished, testing using siRNA delivery in vivo should commence.
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